RECURRENT SMALL LYMPHOCYTIC LYMPHOMA

This study tested a combination of two targeted drugs, venetoclax and ibrutinib, in 234 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal was to see how well the drugs control the cancer, especially in patients whose disease came back or had h…

This study tests whether giving duvelisib on an irregular schedule can still control chronic lymphocytic leukemia or small lymphocytic lymphoma while causing fewer severe side effects. Fifteen adults with cancer that has come back or not responded to treatment will take part. The…

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…

This early-phase study tests a new treatment for adults with B-cell cancers (like lymphoma or leukemia) that returned after prior therapy. Doctors take a patient's own white blood cells, add a gene to help them find and kill cancer cells, and give them back after chemotherapy. Th…

This study tests whether adding rituximab to ibrutinib works better than ibrutinib alone for patients with chronic lymphocytic leukemia (CLL) that has returned after treatment. About 66 adults with relapsed CLL or related blood cancers will receive either ibrutinib alone or ibrut…

This early-stage trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogn…

This early-phase study tests a combination of three drugs (lenalidomide, ibrutinib, and rituximab) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatment. The main goal is to find the safest dose…

This study tests a daily pill called ibrutinib in 154 people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL) that has come back or stopped responding to other treatments. The goal is to see how well the drug con…

This early-phase trial tests the safety and best dose of specially modified T-cells (immune cells) given after a stem cell transplant for people with high-risk or returning non-Hodgkin lymphoma. The modified T-cells are designed to recognize and attack cancer cells. The study inv…

This early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…